- Kronos Bio Inc Phase 1/2 KB-0742 Data Update Call TranscriptOct 13, 2023
- Kronos Bio Inc Annual Shareholders Meeting TranscriptJun 22, 2023
- Kronos Bio Inc at Goldman Sachs Healthcare Conference TranscriptJun 15, 2023
- Kronos Bio Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Kronos Bio Inc at Cowen Health Care Conference TranscriptMar 07, 2023
- Kronos Bio Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptDec 01, 2022
- Kronos Bio Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Kronos Bio Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Kronos Bio Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- Kronos Bio Inc Annual Shareholders Meeting TranscriptJun 22, 2021
- Kronos Bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Kronos Bio Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
Kronos Bio Inc at Piper Sandler Healthcare Conference Transcript
Good morning. My name is Ted Tenthoff. I'm a Senior Biotech Analyst at Piper Sandler. And before I begin, I am required to point out certain disclosures regarding the relationship between Piper and our next presenting company Kronos, which are located at the back of the room and also at the registration desk.
Kronos Bio is developing small molecules that target dysregulated transcription factors and also the associated transcriptional regulation networks, or TRNs, but really with a focus on cancer.
The company is conducting a Phase 1b study of Lanraplenib for -- or what I like to call Lanra because it's little easier to pronounce -- for FLT3-mutant AML. And the company is also conducting a Phase 1/2 study of oral KB-0742 for MYC-Dependent Solid Tumors hopefully with data coming out in the next couple of weeks. The company continues to invest in several discovery programs. So stay tuned. There's going to be a lot more to focus on over the years to come.
Here with us today is Dr. Norbert Bischofberger, President and CEO, and also,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)